RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
Reata Pharmaceuticals Stock

Reata Pharmaceuticals EBIT 2024

Reata Pharmaceuticals EBIT

-89.68 M USD

Ticker

RETA

ISIN

US75615P1030

WKN

A2ALQV

In 2024, Reata Pharmaceuticals's EBIT was -89.68 M USD, a -75.73% increase from the -369.48 M USD EBIT recorded in the previous year.

The Reata Pharmaceuticals EBIT history

YEAREBIT (undefined USD)
2028e-
2027e972.47
2026e531.42
2025e206.32
2024e-89.68
2023e-369.48
2022-278.03
2021-244.71
2020-226.33
2019-285.22
2018-76.88
2017-46.91
2016-6.88
2015-0.33
20143.63
2013-10.38

Reata Pharmaceuticals Revenue, EBIT, Net Income

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details

Revenue, EBIT and Profit

ⓘ

Understanding Revenue, EBIT, and Income

Gain insights into Reata Pharmaceuticals, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by Reata Pharmaceuticals from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects Reata Pharmaceuticals’s net earnings, an ultimate measure of its financial health and profitability.

Yearly Analysis and Comparisons

Observe the yearly bars to understand the annual performance and growth of Reata Pharmaceuticals. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.

Utilizing Expectations for Investment

The expected values for the forthcoming years offer investors a glimpse into Reata Pharmaceuticals’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.

Investment Insights

Leveraging the comparison between Revenue and EBIT helps in assessing Reata Pharmaceuticals’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on Reata Pharmaceuticals’s growth potential.

Reata Pharmaceuticals Revenue, EBIT and net profit per share

DateReata Pharmaceuticals RevenueReata Pharmaceuticals EBITReata Pharmaceuticals Net Income
2028e1.74 B undefined0 undefined450.17 M undefined
2027e1.41 B undefined972.47 M undefined278.53 M undefined
2026e942.78 M undefined531.42 M undefined103.46 M undefined
2025e668.5 M undefined206.32 M undefined105.14 M undefined
2024e405.2 M undefined-89.68 M undefined-150.59 M undefined
2023e92.69 M undefined-369.48 M undefined-228.78 M undefined
20222.22 M undefined-278.03 M undefined-311.9 M undefined
202111.49 M undefined-244.71 M undefined-297.39 M undefined
20209.02 M undefined-226.33 M undefined-247.75 M undefined
201926.52 M undefined-285.22 M undefined-290.17 M undefined
201853.59 M undefined-76.88 M undefined-80.55 M undefined
201748.06 M undefined-46.91 M undefined-47.67 M undefined
201649.86 M undefined-6.88 M undefined-6.23 M undefined
201550.32 M undefined-330,000 undefined-1.45 M undefined
201451.95 M undefined3.63 M undefined690,000 undefined
201351.2 M undefined-10.38 M undefined-35.11 M undefined

Reata Pharmaceuticals stock margins

The Reata Pharmaceuticals margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Reata Pharmaceuticals. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Reata Pharmaceuticals.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details

Margin

ⓘ

Understanding Gross Margin

The gross margin, expressed as a percentage, delineates the gross profit made from the Reata Pharmaceuticals's sales revenue. A higher gross margin percentage indicates that the Reata Pharmaceuticals retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.

EBIT Margin Analysis

EBIT margin represents the Reata Pharmaceuticals's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.

Revenue Margin Insights

The revenue margin demonstrates the Reata Pharmaceuticals's total revenue generated. When comparing the revenue margin year over year, investors can gauge the Reata Pharmaceuticals's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.

Interpreting Expectations

The expected values for gross, EBIT, and revenue margins provide future financial outlook of the Reata Pharmaceuticals. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.

Comparative Analysis

Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the Reata Pharmaceuticals's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.

Reata Pharmaceuticals Margin History

Reata Pharmaceuticals Gross marginReata Pharmaceuticals Profit marginReata Pharmaceuticals EBIT marginReata Pharmaceuticals Profit margin
2028e100 %0 %25.93 %
2027e100 %68.92 %19.74 %
2026e100 %56.37 %10.97 %
2025e100 %30.86 %15.73 %
2024e100 %-22.13 %-37.17 %
2023e100 %-398.61 %-246.82 %
2022100 %-12,546.66 %-14,074.95 %
2021100 %-2,129.75 %-2,588.22 %
2020100 %-2,509.2 %-2,746.67 %
2019-369.08 %-1,075.49 %-1,094.16 %
2018100 %-143.46 %-150.31 %
2017100 %-97.61 %-99.19 %
2016100 %-13.8 %-12.49 %
2015100 %-0.66 %-2.88 %
2014100 %6.99 %1.33 %
2013100 %-20.27 %-68.57 %

Reata Pharmaceuticals Aktienanalyse

What does Reata Pharmaceuticals do?

Reata Pharmaceuticals Inc is a biopharmaceutical company that was founded in Irving, Texas in 2002. The company develops and markets innovative therapeutics for severe and rare diseases, particularly rare genetic metabolic diseases, neurological diseases, and inflammatory diseases. Reata Pharmaceuticals has a unique business model based on the principle of "platform technology". This means that the company develops various therapeutic approaches based on a patented molecular platform. This platform allows Reata to quickly and efficiently develop new products for different disease areas. An important focus of Reata Pharmaceuticals' activities is the development of therapeutics for rare genetic metabolic diseases. The company has made remarkable progress in this area. In particular, the drug Omaveloxolone, which was developed for the treatment of Friedreich's ataxia, has attracted a lot of attention. This rare disease manifests as progressive spastic paralysis and can eventually lead to death. The drug has shown promising results in a Phase 2 study and is currently in Phase 3 study. Another important area for Reata Pharmaceuticals is inflammatory diseases. The company has developed a product called Bardoxolone Methyl, which is approved for the treatment of chronic kidney disease and pulmonary hypertension. These diseases have a significant impact on the quality of life and life expectancy of patients. Bardoxolone Methyl has shown in clinical studies that it can slow disease progression and significantly improve symptoms. In addition to these two pillars of activity, Reata Pharmaceuticals also has various product candidates for neurological diseases, cancer, and other diseases in the pipeline. The company aims to develop innovative solutions for unmet medical needs and help patients whose needs have not been adequately addressed. The history of Reata Pharmaceuticals is characterized by a successful path as a company with a unique business model. The company aims to play a leading role in the development and marketing of therapeutics for rare and serious diseases. To achieve this, the company has built a strong research and development team and works closely with the academic community. Reata Pharmaceuticals has managed to establish an international network of leading scientists, doctors, and patient organizations. This collaboration is crucial for the successful development and marketing of therapeutics for rare diseases. In summary, Reata Pharmaceuticals Inc is an innovative biopharmaceutical company that uses a unique platform technology for the development of therapeutics for rare and severe diseases. The company has made remarkable progress in the development of therapeutics for rare genetic metabolic diseases and inflammatory diseases and is working on additional products for neurological diseases, cancer, and other diseases. Reata Pharmaceuticals aims to play a leading role in the industry and help patients whose needs have not been adequately addressed. Reata Pharmaceuticals ist eines der beliebtesten Unternehmen auf Eulerpool.com.

EBIT Details

Analyzing Reata Pharmaceuticals's EBIT

Reata Pharmaceuticals's Earnings Before Interest and Taxes (EBIT) represents the company's operating profit. It is calculated by deducting all operating expenses, including the cost of goods sold (COGS) and operating expenses, from the total revenue, but before accounting for interest and taxes. It provides insights into the company’s operational profitability, excluding the impacts of financing and tax structures.

Year-to-Year Comparison

A yearly comparison of Reata Pharmaceuticals's EBIT can reveal trends in the company’s operational efficiency and profitability. An increase in EBIT over the years can indicate enhanced operational efficiency or growth in revenue, while a decrease might raise concerns about increased operating costs or declining sales.

Impact on Investments

Reata Pharmaceuticals's EBIT is a significant metric for investors. A positive EBIT suggests that the company is generating enough revenue to cover its operating expenses, an essential aspect for assessing the company’s financial health and stability. Investors closely monitor EBIT to gauge the company’s profitability and potential for future growth.

Interpreting EBIT Fluctuations

Fluctuations in Reata Pharmaceuticals’s EBIT can be due to variations in revenue, operating expenses, or both. An increasing EBIT indicates improved operational performance or increased sales, while a declining EBIT can signal rising operational costs or reduced revenue, prompting a need for strategic adjustments.

Frequently Asked Questions about Reata Pharmaceuticals stock

How much did Reata Pharmaceuticals achieve in EBIT for the current year?

In the current year, Reata Pharmaceuticals has achieved an EBIT of -89.68 M USD.

What is EBIT?

EBIT stands for Earnings Before Interest and Taxes and refers to the profit before interest and taxes of a company Reata Pharmaceuticals.

How has the EBIT of Reata Pharmaceuticals developed in recent years?

The EBIT of Reata Pharmaceuticals has increased by -75.727% decreased compared to the previous year.

What does EBIT mean for investors?

EBIT provides investors with insights into a company's profitability as it reflects the profit before interest expenses and taxes.

Why is EBIT an important indicator for investors?

Since EBIT provides a more direct insight into a company's profit than net income, it is an important indicator for investors to assess the profitability of a company.

Why do EBIT values fluctuate?

EBIT values can fluctuate as they are influenced by various factors, such as revenue, costs, and tax effects.

What role does tax burden play in EBIT?

Tax burdens have a direct impact on a company's EBIT, as they are deducted from the profit.

How is EBIT presented in the balance sheet of the company Reata Pharmaceuticals?

The EBIT of Reata Pharmaceuticals is listed in the income statement.

Can EBIT be used as a single indicator for evaluating a company?

EBIT is an important indicator for evaluating a company, but additional financial ratios should also be considered to get a comprehensive picture.

Why is EBIT not equal to net profit?

The net profit of a company includes taxes and interest, while EBIT represents the profit before interest and taxes.

How much dividend does Reata Pharmaceuticals pay?

Over the past 12 months, Reata Pharmaceuticals paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Reata Pharmaceuticals is expected to pay a dividend of 0 USD.

What is the dividend yield of Reata Pharmaceuticals?

The current dividend yield of Reata Pharmaceuticals is .

When does Reata Pharmaceuticals pay dividends?

Reata Pharmaceuticals pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Reata Pharmaceuticals?

Reata Pharmaceuticals paid dividends every year for the past 0 years.

What is the dividend of Reata Pharmaceuticals?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Reata Pharmaceuticals located?

Reata Pharmaceuticals is assigned to the 'Health' sector.

Wann musste ich die Aktien von Reata Pharmaceuticals kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Reata Pharmaceuticals from 9/29/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 9/29/2024.

When did Reata Pharmaceuticals pay the last dividend?

The last dividend was paid out on 9/29/2024.

What was the dividend of Reata Pharmaceuticals in the year 2023?

In the year 2023, Reata Pharmaceuticals distributed 0 USD as dividends.

In which currency does Reata Pharmaceuticals pay out the dividend?

The dividends of Reata Pharmaceuticals are distributed in USD.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

The Reata Pharmaceuticals stock can be added to a savings plan with the following providers: Trade Republic

Andere Kennzahlen von Reata Pharmaceuticals

Our stock analysis for Reata Pharmaceuticals Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Reata Pharmaceuticals Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.